Interferon β bei Multipler Sklerose

[1]  M. Filippi,et al.  250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study , 2009, The Lancet Neurology.

[2]  J. Skurnick,et al.  Efficacy of treatment of MS with IFN -1b or glatiramer acetate by monthly brain MRI in the BECOME study , 2009 .

[3]  H. Hartung.  High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosis , 2009 .

[4]  F. Barkhof,et al.  Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial , 2008, The Lancet Neurology.

[5]  Sum Lam,et al.  Interferon-β1b for the treatment of multiple sclerosis , 2008, Expert opinion on drug metabolism & toxicology.

[6]  S. Sorbi,et al.  Long-Term Adherence to Interferon β Therapy in Relapsing-Remitting Multiple Sclerosis , 2007, European Neurology.

[7]  P. Rieckmann.  [Escalating immunomodulatory therapy of multiple sclerosis. Update (September 2006)]. , 2006, Der Nervenarzt.

[8]  M. Filippi,et al.  Glatiramer acetate therapy for multiple sclerosis: a review , 2006, Expert opinion on drug metabolism & toxicology.

[9]  L. Durelli,et al.  Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with NAb , 2006, Multiple sclerosis.

[10]  D. Goodin,et al.  Benefits of high-dose, high-frequency interferon beta-1a in relapsing–remitting multiple sclerosis are sustained to 16 months: Final comparative results of the EVIDENCE trial , 2005, Journal of the Neurological Sciences.

[11]  P. Chang,et al.  The long‐term safety and tolerability of high‐dose interferon β‐1a in relapsing–remitting multiple sclerosis: 4‐year data from the PRISMS study , 2005, European journal of neurology.

[12]  D. Goodin,et al.  Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study. , 2005, Archives of neurology.

[13]  G. Francis.  Benefit-risk assessment of interferon-b therapy for relapsing multiple sclerosis , 2004, Expert opinion on drug safety.

[14]  D. Brunet,et al.  Lipoatrophy in Patients with Multiple Sclerosis on Glatiramer Acetate , 2004, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[15]  D. Goodin,et al.  Randomized, comparative study of interferon &bgr;-1a treatment regimens in MS: The EVIDENCE Trial , 2002 .

[16]  M. Mcdermott,et al.  Needed in MS: evidence, not EVIDENCE. , 2002, Neurology.

[17]  F. Lublin.  When marketing and science intersect: do patients with MS benefit? , 2002, Neurology.

[18]  S. Engelter,et al.  CADASIL mimicking primary angiitis of the central nervous system. , 2002, Archives of neurology.

[19]  A. Ghezzi,et al.  Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN) , 2002, The Lancet.

[20]  A. Compston,et al.  Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.

[21]  Richard A. C. Hughes,et al.  PRISMS-4: Long-term efficacy of interferon-&bgr;-1a in relapsing MS , 2001, Neurology.

[22]  Massimo Filippi,et al.  European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis , 2001, Annals of neurology.

[23]  L. Blumhardt,et al.  Randomised, double blind, placebo controlled study of interferon β-1a in relapsing-remitting multiple sclerosis analysed by area under disability/time curves , 1999, Journal of neurology, neurosurgery, and psychiatry.

[24]  D. Paty,et al.  Magnetic resonance imaging results of the PRISMS trial: A randomized, double‐blind, placebo‐controlled study of interferon‐β1a in relapsing‐remitting multiple sclerosis , 1999 .

[25]  P. Rieckmann,et al.  Immunmodulatorische Stufentherapie der Multiplen Sklerose , 1999, Der Nervenarzt.

[26]  G. Ebers,et al.  Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis , 1998, The Lancet.

[27]  Jeanelle Sheeder,et al.  Magnetic resonance studies of intramuscular interferon β–1a for relapsing multiple sclerosis , 1998 .

[28]  C. Granger,et al.  Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.

[29]  J. W. Rose,et al.  Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis , 1995, Neurology.

[30]  R. Knobler,et al.  Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. , 1993, Journal of interferon research.

[31]  D. Paty,et al.  Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.

[32]  P. Duquette,et al.  Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. , 1993 .

[33]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[34]  U. Mrowietz,et al.  Localized Panniculitis and Subsequent Lipoatrophy with Subcutaneous Glatiramer Acetate (Copaxone®) Injection for the Treatment of Multiple Sclerosis , 2004, American journal of clinical dermatology.